



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**31 August 2021**

---

**CORRECTION TO APPENDIX 4E**

The Appendix 4E issued by Bionomics Limited (ASX:BNO) on 25 August 2021 incorrectly stated the values for Net tangible asset backing per ordinary share.

A corrected Appendix 4E is attached.

**AUTHORISED BY THE BOARD.**  
**FOR FURTHER INFORMATION PLEASE CONTACT:**

**MS SUZANNE IRWIN**  
**COMPANY SECRETARY**  
**BIONOMICS LIMITED**  
**Ph: +61 8 8150 7400**

**MR ADRIAN HINTON**  
**ACTING CFO**  
**BIONOMICS LIMITED**  
**Ph: + 61 8 8150 7400**

**About Bionomics Limited**

Bionomics (ASX: BNO, OTCQB: BNOEF) is a clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best-in-class, novel drug candidates for patients affected by central nervous system (CNS) disorders. Bionomics' lead drug candidate BNC210 is a negative allosteric modulator of the  $\alpha 7$  nicotinic acetylcholine receptor. BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA. BNC210 is also being evaluated as an acute treatment in Social Anxiety Disorder (SAD) patients and is expected to enter a Phase 2 trial. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences, to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4- Methylenedioxymethamphetamine (MDMA) derivative EMP-01 for the treatment of PTSD. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

[www.bionomics.com.au](http://www.bionomics.com.au)



ABN 53 075 582 740

## BIONOMICS LIMITED

Year ended 30 June 2021

(previous corresponding period: year ended 30 June 2020)

### Results for Announcement to the Market

\$

<b>Cash and cash equivalents as at 30 June 2021 from 30 June 2020</b>	increased by	523%	to	28,499,449
<b>Net operating and investing cash outflows for the period</b>	increased by	86%	to	7,618,930
<b>Revenue from continuing operations</b>	decreased by	100%	to	NIL
<b>Other income from continuing operations</b>	decreased by	61%	to	1,308,343
<b>Other gains and losses from continuing operations</b>	decreased by	7%	to	4,272,931
<b>Loss from continuing operations after tax</b>	increased by	49%	to	8,697,037
<b>Loss from discounted operations</b>	decreased by	100%	to	NIL
<b>Loss for the year</b>	decreased by	22%	to	8,697,037

### NTA Backing

	<b><u>2021</u></b>	<b><u>2020</u></b>
Net tangible asset backing per ordinary share	\$0.03	(\$0.01) cents

### Explanation of cash and cash equivalents position as at 30 June 2021:

The closing cash and cash equivalents position is in line with expectations and reflects net proceeds from share issues offset by repayments of borrowing and net cash used in operating activities (principally relating to research and development activities).

### Explanation of net movement in operating and investing cash outflows:

The net movement includes ongoing core R&D expenditure on the Company's clinical programs BNC210 and the continued development of the product pipeline.

### Explanation of revenue from continuing operations:

In the current period there was no revenue, prior period revenue (\$46,662) related to licence fees received.

### **Explanation of other income from continuing operations**

Other income predominately consists of the Australian R&D Tax incentive and has decreased as a result of reduced eligible research and development expenditure.

### **Explanation of loss from continuing operations after tax:**

The increase in current year loss from continuing operations principally reflects the reduction in other income, and other gains and losses and increase in expenses (administration expenses offset by reduction in finance expenses).

### **Explanation of loss from discontinued operations**

The loss from discontinued operation only relates to the year ended 30 June 2020, as on 3 March 2020, the Company sold its two wholly owned French subsidiaries, Neurofit SAS and PC SAS, which carry out all the Group's contract service business resulting in a loss on disposal of \$1,299,313.

### **Explanation of loss for the year**

The increase in current year loss principally reflects the reduction in other income, and other gains and losses and a net increase in expenses (increase in administration expenses offset by reduction in finance expenses) offset by effect of the loss on disposals the Company's two French subsidiaries that occurred during the year end 30 June 2020 as there was no discontinued operations for the year end 30 June 2021.

### **Dividends/Distributions**

Bionomics Limited does not propose to pay any dividend for the year ended 30 June 2021.